Morepen Laboratories Limited has informed the Exchange about Amendment to BTA
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories has approved a Second Addendum to its Business Transfer Agreement with subsidiary Morepen Medipath Limited (formerly Morepen Medtech Ltd). The amendment revises the 'Appointed Date' for transferring the Medical Devices Business to April 1, 2026, due to delays in obtaining statutory licenses and regulatory approvals. The slump sale consideration is Rs. 19,710.12 lakhs. The Board also approved FY2026 audited results showing standalone net profit of Rs. 660.58 crore and recommended a final dividend of Rs. 0.20 per share. This is a related party transaction conducted at arm's length, with the company holding 51% of MML and promoters holding additional 42.89%.
The business transfer to subsidiary effectively reorganizes the Medical Devices segment under Morepen Medipath. While net profit declined year-over-year, the transaction is internal and should not materially impact the listed entity's fundamentals. Shareholders may benefit from focused pharmaceutical operations.